Dissociation Between Clinical Benefit and Persistent Urate Lowering in Patients with Chronic Refractory Gout Treated with Pegloticase

Gout

Characterization of patients with chronic refractory gout who do and do not have clinically apparent tophi and their response to pegloticase

Rheumatology (Oxford).

Lawrence Edwards N, Singh JA, Troum O, Yeo AE, Lipsky PE

doi: 10.1093/rheumatology/

Gout

A retrospective analysis of medication prescription records for determining the levels of compliance and persistence to urate-lowering therapy for the treatment of gout and hyperuricemia in The Netherlands

Clin Rheumatol.

Janssen CA, Oude Voshaar MAH, Vonkeman HE, Krol M, van de Laar MAFJ

doi: 10.1007/s10067-018-4127-x.

Gout

Rate of adherence to urate-lowering therapy among patients with gout: a systematic review and meta-analysis

BMJ Open.

Yin R, Li L, Zhang G, Cui Y, Zhang L, Zhang Q, Fu T, Cao H, Li L, Gu Z

doi: 10.1136/

Gout

Ultrasound evaluation in follow-up of urate-lowering therapy in gout: the USEFUL study

Rheumatology (Oxford).

Ebstein E, Forien M, Norkuviene E, Richette P, Mouterde G, Daien C, Ea HK, Brière C, Lioté F, Petraitis M, Bardin T, Ora J, Dieudé P, Ottaviani S

doi: 10.1093/rheumatology/key303.

Psoriasis

Benefit-risk of tofacitinib in patients with moderate to severe chronic plaque psoriasis: Pooled analysis across 6 clinical trials

Br J Dermatol.

Strober BE, Gottlieb AB, van de Kerkhof PCM, Puig L, Bachelez H, Chouela E, Imafuku S, Thaçi D, Tan H, Valdez H, Gupta P, Kaur M, Frajzyngier V, Wolk R

doi: 10.1111/bjd.17149.

Gout

Ultrasound shows rapid reduction of crystal depositions during a treat-to-target approach in gout patients: 12-month results from the NOR-Gout study

Ann Rheum Dis.

Hammer HB, Karoliussen L, Terslev L, Haavardsholm EA, Kvien TK, Uhlig T

doi: 10.1136/annrheumdis-2020-217392.

COMMENTED

Melanoma and Skin Cancer

Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials

JAMA Oncol.

Long GV, Weber JS, Larkin J, Atkinson V, Grob JJ, Schadendorf D, Dummer R, Robert C, Márquez-Rodas I, McNeil C, Schmidt H, Briscoe K, Baurain JF, Hodi FS, Wolchok JD

doi: 10.1001/

Treatment response to omalizumab in patients with refractory chronic spontaneous urticaria

Int J Dermatol.

Syrigos N, Grapsa D, Zande M, Tziotou M, Syrigou E

doi: 10.1111/ijd.13935.

Gout

Major unanswered questions in the clinical gout field.

Curr Opin Rheumatol.

Stamp LK

doi: 10.1097/BOR.00000000

Related content

Characterization of patients with chronic refractory gout who do and do not have clinically apparent tophi and their response to pegloticase

A retrospective analysis of medication prescription records for determining the levels of compliance and persistence to urate-lowering therapy for the treatment of gout and hyperuricemia in The Netherlands

Rate of adherence to urate-lowering therapy among patients with gout: a systematic review and meta-analysis

Ultrasound evaluation in follow-up of urate-lowering therapy in gout: the USEFUL study

Benefit-risk of tofacitinib in patients with moderate to severe chronic plaque psoriasis: Pooled analysis across 6 clinical trials

Ultrasound shows rapid reduction of crystal depositions during a treat-to-target approach in gout patients: 12-month results from the NOR-Gout study

Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials

Treatment response to omalizumab in patients with refractory chronic spontaneous urticaria

Major unanswered questions in the clinical gout field.